BerGenBio ASA: Invitation to fourth quarter 2022 results webcast
Bergen, Norway, 1 February 2023 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the fourth quarter 2022 on Thursday 16 February 2023. The briefing will take place at 10:00 am CET at:Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslowhere BerGenBio's senior management team will provide an update on the Company followed by a Q&A session. To attend in person please register by mail to ir@bergenbio.com The presentation will webcast live and a